Antifungal therapy in pediatric patients

Current Fungal Infection Reports

Volumn 5, Issue 2, 2011, Pages 103-110

  Lehrnbecher, Thomas ^a   Bochennek, Konrad ^a   Schrey, Dominik ^b   Groll, Andreas H ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

5 Fluorocytosine; Amphotericin B deoxycholate; Anidulafungin; Caspofungin; Child; Fluconazole; Invasive fungal infection; Itraconazole; Lipid formulations of amphotericin B; Micafungin; Neonate; Posaconazole; Preterm; Voriconazole

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ARTICLE; DOSE RESPONSE; DRUG ERUPTION; DRUG FEVER; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NEPHROTOXICITY; PHOTOSENSITIVITY DISORDER; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; VISUAL IMPAIRMENT;

EID: 79960278290     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0046-x     Document Type: Article

References (57)

1. Nath CE, Shaw PJ, Gunning R, et al. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother. 1999;43:1417-23. (Pubitemid 29259336)
2. Kingo AR, SmythJA, WaismanD.Lackofevidenceof amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J. 1997;16:1002-3. (Pubitemid 27452322)
3. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28:1061-3.
4. Groll AH, Piscitelly TJ, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-500.
5. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14 Suppl 4:25-36. (Pubitemid 351593914)
6. Amantea MA, Bowden RA, Forrest A, et al. Population pharmacokinetics and renal function-sparing effects ofamphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995;39:2042-7.
7. Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol. 2000;22:242-6. (Pubitemid 32268308)
8. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997;41:1944-8. (Pubitemid 27383233)
9. Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41:2201-8. (Pubitemid 27422213)
10. Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49:5092-8. (Pubitemid 41778925)
11. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J. 2005;24:167-74. (Pubitemid 40250777)
12. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J. 1999;18:702-8. (Pubitemid 29382466)
13. Walsh T, Shad A, Bekersky I, et al. Safety, tolerability and pharmacokinetics of liposomal amphotericin B in immunocompro-mised pediatric patients [abstract], 2008. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25-28, 2008: A-005.
14. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother. 1998;42:2391-8. (Pubitemid 28420384)
15. Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006;50:935-42. (Pubitemid 43327797)
16. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-8. (Pubitemid 27386554)
17. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17:146-8. (Pubitemid 28096014)
18. Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Pädiatr. 2005;217 Suppl 1:S37-66. (Pubitemid 41746054)
19. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52:4043-9.
20. Wade KC, Benjamin Jr DK, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28:717-23. This important, population-based pharmacokinetic study led to changes in dosing of fluconazole in neonates and young infants.
21. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother. 1999;43:1955-60. (Pubitemid 29395192)
22. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-6. (Pubitemid 33126821)
23. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356:2483-95. (Pubitemid 46919774)
24. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002;46:2554-63. (Pubitemid 34793463)
25. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006;45:1099-114. (Pubitemid 44631389)
26. Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007;51:2668-73. (Pubitemid 47206198)
27. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791-7. (Pubitemid 20162837)
28. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59:791-3. (Pubitemid 47073421)
29. Francis P, Walsh T. Evolving role offlucytosine in immunocompomied patients: new insights into safety, pharmacokinetic, and antifungal therapy. Clin Infect Dis. 1992;15:1003-18.
30. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-72. (Pubitemid 38691615)
31. Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25-31.
32. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935-44.
33. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
34. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54:1050-2.
35. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240-8. (Pubitemid 34214142)
36. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62:31-7.
37. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812-8. (Pubitemid 46355260)
38. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043-5.
39. Benjamin Jr DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632-8. (Pubitemid 43190976)
40. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215-22.
41. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536-45. (Pubitemid 41552583)
42. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53:1450-6.
43. Li C, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients [abstract]. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25-28, 2008: A-006.
44. Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53:869-75.
45. Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009;28:1132-5.
46. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29:415-20. This randomized, multicenter study demonstrates that caspofungin and liposomal amphotericin B are comparable in tolerability, safety, and efficacy as empiric antifungal therapy for persistently febrile, neutropenic pediatric patients.
47. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391-402.
48. Groll AH, Stergiopoulou T, Roilides E, Walsh T. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005;14:489-509. (Pubitemid 40711857)
49. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-24. (Pubitemid 41060577)
50. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacoki-netics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714-9. (Pubitemid 47519363)
51. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-5. (Pubitemid 44900673)
52. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-71. (Pubitemid 351263481)
53. Hope WW, Smith PB, Arrieta A, et al. Population pharmaco-kinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633-7. The results ofthis important study suggest the need for higher doses of micafungin in premature neonates.
54. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412-5.
55. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820-6. This pediatric substudy, as part ofa double-blind, randomized, multinational trial, included 106 children to compare micafungin (2 mg/kg) with liposomal amphotericin B (3 mg/kg) as first-line treatment of invasive candidiasis.
56. Arrieta A, Maddison P, Groll AH. Micafungin in pediatric patients: assessment of safety in clinical trials [abstract], 2007. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17-20, 2007: M-1162.
57. Mycamine Summary of Product Characterization. Available at http:// www.emea.europa.eu/humandocs/humans/EPAR/mycamine/ mycamine.htm. Accessed January 10, 2011.